Aura Biosciences (NASDAQ:AURA) Raised to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Aura Biosciences (NASDAQ:AURA) to a strong-buy rating in a research note published on Friday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. BTIG Research lifted their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Finally, Scotiabank raised their target price on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Aura Biosciences presently has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Down 1.0 %

NASDAQ AURA opened at $7.85 on Friday. The firm’s fifty day simple moving average is $8.28 and its two-hundred day simple moving average is $8.90. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. On average, analysts predict that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,778 shares of company stock worth $240,706. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its stake in Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares in the last quarter. State Street Corp increased its holdings in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares during the last quarter. Geode Capital Management LLC lifted its position in Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after buying an additional 39,379 shares in the last quarter. Wellington Management Group LLP acquired a new position in Aura Biosciences during the third quarter worth $1,037,000. Finally, Franklin Resources Inc. grew its holdings in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.